PCL Inc is a Korea-based company principally engaged in development and manufacture of vitro diagnostic medical device for immunological diagnosis. The Companyâ€™s products include blood bank screening products and quick diagnostic products. And the Company also provides platform services.

Employees

Sector

Biotechnology & Medical Research

More about the company

End-of-day quote Korea S.E. 2025-03-21			5-day change	1st Jan Change
6,040.00 ^KRW	-1.63%		-.--%	-

24-12-29	Yeom Ju-hwan agreed to acquire 36.90% stake in mCureX Therapeutics, Inc. from PCL, Inc. for KRW 13.0 billion.	CI
24-08-29	PCL, Inc. announced that it has received KRW 4.004999835 billion in funding	CI

Market Cap	16.8B 12.48M 10.73M 10.09M 9.21M 17.23M 1.18B 17.29M 120M 46.27M 604M 46.87M 45.84M 1.93B	P/E 2023	-7.17x	P/E 2024	-0.59x
Enterprise Value	23.83B 17.7M 15.22M 14.32M 13.07M 24.44M 1.67B 24.52M 170M 65.62M 857M 66.48M 65.02M 2.73B	EV / Sales 2023	22.8x	EV / Sales 2024	31.9x
Free-Float	98.99%	Yield 2023 *	-	Yield 2024	-

24-12-29	Yeom Ju-hwan agreed to acquire 36.90% stake in mCureX Therapeutics, Inc. from PCL, Inc. for KRW 13.0 billion.	CI
24-08-29	PCL, Inc. announced that it has received KRW 4.004999835 billion in funding	CI
24-08-21	PCL, Inc. announced that it expects to receive KRW 4.004999835 billion in funding	CI
24-06-24	PCL, Inc. announced that it has received KRW 9.99999838 billion in funding from JS & Partners Co., Ltd.	CI
24-06-20	Tiger Company Ltd. announced that it has received KRW 8.3 billion in funding from PCL, Inc.	CI
24-01-15	PCL, Inc. announced that it has received KRW 9.99999885 billion in funding from Global Emerging Markets	CI
23-12-25	PCL, Inc. announced that it has received KRW 9.99999838 billion in funding from Global Emerging Markets	CI
23-12-20	PCL, Inc. announced that it expects to receive KRW 9.99999885 billion in funding from Global Emerging Markets	CI
23-12-14	PCL, Inc. announced that it expects to receive KRW 9.99999838 billion in funding from JS & Partners Co., Ltd.	CI
23-05-31	South Korean Stocks Close Lower as Uncertainties Around US Debt Ceiling Deal Remain; PCL Loses 13%	MT
23-05-31	PCL to Raise 36 Billion Won via Share Issuance	MT
23-03-22	PCL, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	CI
22-12-28	PCL, Inc. announced that it has received KRW 2.999990812 billion in funding from Hyeopsim Co ., Ltd.	CI

3 years	5,900	94,500
5 years	5,900	340,000
10 years	5,900	523,333.33

PCL, Inc. Stock

Stocks

A241820

KR7241820000

Biotechnology & Medical Research

Valuation : PCL, Inc.

Latest news : PCL, Inc.

Quotes and Performance

Price Extremes

Managers and Directors : PCL, Inc.

Bio Diagnostics & Testing

Financials

Company Profile

Manager	Title	Age	Since
So-Yeon Kim CEO	Chief Executive Officer	55	-
Seong-Woo Lee SAM	Sales & Marketing	42	2024-03-27
Mu-Yong So AUD	Comptroller/Controller/Auditor	53	2024-03-27

Director	Title	Age	Since
So-Yeon Kim BRD	Director/Board Member	55	-
Chul-Joon Kim BRD	Director/Board Member	74	-
Mu-Yong So BRD	Director/Board Member	53	2024-03-27

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
PCL, INC.	-1.63%	-.--%	-.--%	-89.08%	12.48M
IOVANCE BIOTHERAPEUTICS, INC.	+1.03%	+7.59%	+253.01%	+51.55%	3.98B
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-1.18%	-2.57%	+88.95%	+285.40%	3.87B
VERACYTE, INC.	-4.79%	-1.53%	+31.14%	+67.90%	3.42B
CAREDX, INC.	+2.05%	+1.54%	+268.16%	+515.98%	2.63B
BGI GENOMICS CO., LTD.	+0.05%	-5.14%	-27.77%	-29.70%	2.11B
FREENOME, INC.	-3.49%	+10.28%	+54.60%	-	1.75B
MARAVAI LIFESCIENCES HOLDINGS, INC.	-0.68%	-4.19%	+191.63%	-33.99%	1.09B
SEEGENE, INC.	-1.57%	-6.55%	+21.47%	+43.05%	1.06B
CURIOX BIOSYSTEMS CO., LTD	+6.40%	-1.93%	+9.03%	+54.34%	648M
Average	-0.38%	-0.20%	+89.02%	+96.16%	2.06B
Weighted average by Cap.	-0.77%	+1.03%	+118.51%	+153.03%

	2023	2024
Net sales	8.43B 6.26M 5.38M 5.06M 4.62M 8.65M 592M 8.67M 60.04M 23.21M 303M 23.51M 23M 966M	1.25B 926K 796K 749K 683K 1.28M 87.53M 1.28M 8.88M 3.43M 44.82M 3.48M 3.4M 143M
Net income	-20.32B -15.09M -12.98M -12.21M -11.14M -20.84M -1.43B -20.91M -145M -55.94M -731M -56.67M -55.43M -2.33B	-52.34B -38.87M -33.43M -31.44M -28.7M -53.68M -3.68B -53.85M -373M -144M -1.88B -146M -143M -6B
Net Debt	7.2B 5.35M 4.6M 4.33M 3.95M 7.39M 506M 7.41M 51.31M 19.83M 259M 20.09M 19.65M 825M	7.03B 5.22M 4.49M 4.22M 3.86M 7.21M 494M 7.23M 50.07M 19.36M 253M 19.61M 19.18M 805M